---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000495"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:26:40.634856+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sarepta prelim Q4 revenue $235.5M, FY $843.3M, exceeding guidance

## Summary
- Preliminary Q4 2022 net product revenue ~$235.5M, up 32% YoY.
- Full-year 2022 net product revenue ~$843.3M, up 38% YoY, exceeding guidance of $825-840M.
- Year-end cash balance ~$2.0B, down slightly from $2.1B at end of 2021.
- Revenues from three RNA-based PMO therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45.
- Final Q4/FY results expected in late February 2023.

## SEC filing metadata
- accession: 0000950170-23-000495
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/0000950170-23-000495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/srpt-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000495
- JSON: https://secwatch.observer/filing/0000950170-23-000495.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000495.txt

## Key facts
- Earnings Releases
  Sarepta Therapeutics, Inc. reported year ended December 31, 2022 results: revenue approximately $843.3 million.
  - Period: year ended December 31, 2022
  - Revenue: approximately $843.3 million
  - Result: preliminary results
  source text: expects total net product revenue (unaudited) for the year ended December 31, 2022 to be approximately $843.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/0000950170-23-000495-index.htm
- Earnings Releases
  Sarepta Therapeutics, Inc. reported fourth quarter ended December 31, 2022 results: revenue approximately $235.5 million.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: approximately $235.5 million
  - Result: preliminary results
  source text: the Company expects total net product revenue (unaudited) for the fourth quarter ended December 31, 2022 to be approximately $235.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000095017023000495/0000950170-23-000495-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.